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OBJECTIVE—To assess the association between diagnosed diabetes and self-reported cancer
among U.S. adults.
RESEARCH DESIGN AND METHODS—We analyzed data for 397,783 adults who
participated in the 2009 Behavioral Risk Factor Surveillance System and had valid data on di-
abetes and cancer.
RESULTS—After adjustment for potential confounders, diabetic men had higher adjusted
prevalence ratios for cancers of the prostate (1.1 [95% CI 1.0–1.3]), colon (1.3 [1.0–1.7]),
pancreas (4.6 [1.8–11.7]), rectum (2.2 [1.0–4.7]), urinary bladder (1.7 [1.2–2.2]), and kidney
(1.9 [1.2–3.0]) than nondiabetic men (all P , 0.05). Diabetic women had higher adjusted
prevalence ratios for cancers of the breast (1.1 [1.0–1.3]) and endometrium (1.6 [1.2–2.0]),
and leukemia (2.3 [1.3–4.2]) than nondiabetic women (all P , 0.05).
CONCLUSIONS—Ourresults suggest thatdiabeticadults havehigherprevalencesof certain
cancers than nondiabetic adults.
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D
iabetesandcanceraretwocommon
chronic diseases that exert serious
adverse effects on public health in
theU.S.Approximately25.6millionadults
(11.3%) aged 20 years or older were es-
timated to have diabetes in 2010 (1). Ap-
proximately 11.7 million Americans were
living with cancer in 2007. Studies have
found that diabetes is associated with an
increased risk for certain types of cancer
(2,3), and diabetes may increase the risk
of all-cause mortality among people with
cancer (4). To compare the prevalence of
cancer between adults without and with
diabetes, we analyzed a large population–
basedsamplefromtheCentersforDisease
Control and Prevention 2009 Behavioral
Risk Factor Surveillance System (BRFSS)
in the U.S.
RESEARCH DESIGN AND
METHODS—The BRFSS is a standard-
ized telephone survey that annually as-
sesses key behavioral risk factors and
chronic diseases among adults aged 18
years or older in all U.S. states, District of
Columbia, and territories. The median
cooperation rate among states was 75.0%
in 2009 (5). BRFSS data have consistently
provided valid and reliable estimates
compared with national household sur-
veys (6,7).
Diabetes status was ascertained by
asking participants, “Have you ever been
told by a doctor that you have diabetes?”
Responses were coded as “yes,”“ yes, but
female told only during pregnancy,” or
“no.” Gestational diabetes was coded as
“no” diabetes.
Cancer status was ascertained by ask-
ingparticipants,“Haveyoueverbeentold
by a doctor, nurse, or other health pro-
fessional that you have cancer?” Respon-
seswere coded as “yes,”or“no.”Forthose
who answered “yes” to this question, the
following questions were asked, “With
your most recent diagnoses of cancer,
what type of cancer was it?” The survey
included 10 major cancer sites/tracts and
29 cancer types: breast cancer, male re-
productive tract (prostate cancer, testicu-
lar cancer), head/neck (head and neck
cancer, oral cancer, pharyngeal cancer,
thyroid cancer), gastrointestinal tract (co-
lon cancer, esophageal cancer, liver can-
cer, pancreatic cancer, rectal cancer,
stomach cancer), leukemia/lymphoma
(Hodgkin’s lymphoma, leukemia, non–
Hodgkin’s lymphoma), skin (melanoma,
other skin cancer), lung cancer, urinary
tract (urinary bladder cancer, kidney can-
cer), and other sites (heart cancer, bone
cancer, brain cancer, neuroblastoma,
other).
Demographic characteristics in-
cluded sex, age (year), and race/ethnicity
(non–Hispanic white, non–Hispanic
black, Hispanic, and other). Health-
related risk factors included health insur-
ancecoverage(nonevs.anytypeofhealth
insurance), smoking status (current
smoker, former smoker, and never
smoked), heavy drinking (consuming
more than two drinks per day among
men and more than one drink per day
among women), BMI (kg/m
2), and phys-
ical inactivity.
We estimated the crude prevalence
for cancer of all sites and speciﬁct y p e so f
cancer according to diabetes status. We
estimated the prevalence ratios and their
95% CIs using log-linear models with a
robust error variance estimator (8). The
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BRIEF REPORTTable 1—Prevalences and prevalence ratios of cancer according to diabetes status among men and women, BRFSS 2009
Cancer site/tract Cancer type
Crude prevalence, % (SE) Prevalence ratio (95% CI)
Diabetes No diabetes P Model 1* Model 2† Model 3‡
Men, N 19,719 131,740
All cancers 15.89 (0.45) 7.49 (0.11) ,0.0001 2.1 (2.0–2.3) 1.1 (1.0–1.1) 1.1 (1.1–1.2)
Breast cancer 0.10 (0.04) 0.02 (0.01) 0.029 5.2 (2.1–12.7) 3.0 (1.2–7.1) 1.5 (0.4–4.8)
Male reproductive 5.35 (0.31) 2.06 (0.06) ,0.0001 2.6 (2.3–3.0) 1.1 (1.0–1.3) 1.1 (1.0–1.3)
Prostate 5.11 (0.31) 1.89 (0.05) ,0.0001 2.7 (2.4–3.1) 1.2 (1.0–1.3) 1.1 (1.0–1.3)
Testicular 0.27 (0.06) 0.18 (0.03) 0.20 1.5 (0.9–2.5) 1.2 (0.7–2.1) 1.1 (0.5–2.2)
Head/neck 0.58 (0.09) 0.27 (0.02) 0.0006 2.2 (1.6–3.1) 1.2 (0.8–1.6) 1.2 (0.8–1.7)
Head and neck 0.11 (0.04) 0.06 (0.01) 0.18 1.9 (0.9–3.8) 1.0 (0.5–2.0) 1.2 (0.6–2.5)
Oral 0.07 (0.03) 0.05 (0.01) 0.43 1.5 (0.6–3.4) 0.9 (0.4–1.8) 0.9 (0.4–2.1)
Pharyngeal 0.14 (0.04) 0.06 (0.01) 0.066 2.2 (1.2–4.2) 1.0 (0.5–1.9) 1.0 (0.5–1.9)
Thyroid 0.26 (0.07) 0.10 (0.01) 0.014 2.7 (1.5–4.8) 1.6 (0.9–2.8) 1.4 (0.8–2.6)
Gastrointestinal 1.90 (0.17) 0.58 (0.03) ,0.0001 3.2 (2.7–4.0) 1.5 (1.2–1.8) 1.4 (1.2–1.8)
Colon 1.37 (0.15) 0.42 (0.02) ,0.0001 3.2 (2.5–4.1) 1.5 (1.1–1.8) 1.3 (1.0–1.7)
Esophageal 0.03 (0.01) 0.03 (0.01) 0.95 1.0 (0.5–2.1) 0.4 (0.2–0.9) 0.6 (0.3–1.4)
Liver 0.12 (0.04) 0.03 (0.01) 0.022 3.7 (1.8–7.6) 1.9 (0.9–4.0) 1.8 (0.9–3.4)
Pancreatic 0.16 (0.07) 0.02 (0.01) 0.034 7.0 (2.8–17.3) 3.4 (1.4–8.3) 4.6 (1.8–11.7)
Rectal 0.14 (0.04) 0.03 (0.01) 0.003 4.7 (2.6–8.8) 2.1 (1.1–4.0) 2.2 (1.0–4.7)
Stomach 0.09 (0.03) 0.04 (0.01) 0.12 2.2 (1.0–4.5) 1.1 (0.5–2.2) 1.0 (0.4–2.5)
Leukemia/lymphoma 0.68 (0.10) 0.44 (0.04) 0.026 1.6 (1.1–2.2) 1.0 (0.7–1.4) 1.1 (0.8–1.6)
Hodgkin’s
lymphoma
0.32 (0.08) 0.14 (0.02) 0.023 2.4 (1.4–4.1) 1.7 (0.9–3.0) 1.8 (0.9–3.4)
Leukemia 0.15 (0.04) 0.13 (0.02) 0.61 1.2 (0.7–2.1) 0.7 (0.4–1.2) 0.8 (0.5–1.6)
Non–Hodgkin’s
lymphoma
0.21 (0.05) 0.17 (0.03) 0.53 1.2 (0.7–2.2) 0.8 (0.5–1.4) 0.8 (0.4–1.4)
Skin 5.57 (0.27) 3.09 (0.06) ,0.0001 1.8 (1.6–2.0) 0.9 (0.8–1.0) 1.0 (0.9–1.1)
Melanoma 2.01 (0.15) 0.99 (0.04) ,0.0001 2.0 (1.7–2.4) 1.0 (0.8–1.2) 1.1 (0.9–1.3)
Other skin 3.71 (0.23) 2.14 (0.05) ,0.0001 1.7 (1.5–2.0) 0.9 (0.8–1.0) 1.0 (0.9–1.1)
Lung 0.38 (0.06) 0.19 (0.02) 0.0036 2.0 (1.3–2.9) 0.9 (0.6–1.3) 0.8 (0.5–1.4)
Urinary 1.35 (0.14) 0.33 (0.02) ,0.0001 4.1 (3.2–5.1) 1.8 (1.4–2.3) 1.7 (1.3–2.2)
Bladder 0.86 (0.11) 0.22 (0.02) ,0.0001 4.0 (3.0–5.3) 1.7 (1.3–2.3) 1.7 (1.2–2.2)
Kidney 0.50 (0.09) 0.12 (0.01) ,0.0001 4.3 (2.9–6.4) 2.2 (1.4–3.3) 1.9 (1.2–3.0)
Other sites 1.53 (0.15) 0.70 (0.04) ,0.0001 2.2 (1.8–2.7) 1.2 (1.0–1.5) 1.2 (1.0–1.6)
Heart Rare§ Rare — ———
Bone 0.11 (0.04) 0.06 (0.02) 0.28 1.9 (0.7–4.9) 1.6 (0.7–3.9) 1.5 (0.6–3.7)
Brain 0.07 (0.03) 0.04 (0.01) 0.33 1.7 (0.7–3.9) 1.6 (0.7–4.0) 2.2 (0.9–5.6)
Neuroblastoma Rare Rare — ———
Other 1.36 (0.14) 0.60 (0.03) ,0.0001 2.3 (1.8–2.8) 1.2 (0.9–1.5) 1.2 (1.0–1.5)
Women, N 28,699 217,625
All cancers 17.08 (0.39) 10.37 (0.11) ,0.0001 1.7 (1.6–1.7) 1.1 (1.0–1.1) 1.1 (1.1–1.2)
Breast 5.52 (0.24) 2.87 (0.06) ,0.0001 1.9 (1.8–2.1) 1.1 (1.0–1.2) 1.1 (1.0–1.3)
Reproductive 4.08 (0.25) 2.22 (0.06) ,0.0001 1.8 (1.6–2.1) 1.5 (1.3–1.7) 1.3 (1.2–1.6)
Cervical 1.87 (0.15) 1.36 (0.05) 0.0011 1.4 (1.2–1.6) 1.3 (1.1–1.6) 1.2 (1.0–1.5)
Endometrial 1.45 (0.17) 0.45 (0.02) ,0.0001 3.2 (2.5–4.1) 2.0 (1.6–2.6) 1.6 (1.2–2.0)
Ovarian 0.87 (0.13) 0.44 (0.03) 0.0011 2.0 (1.4–2.7) 1.5 (1.1–2.1) 1.4 (0.9–2.0)
Head/neck 0.67 (0.08) 0.42 (0.02) 0.0023 1.6 (1.2–2.1) 1.1 (0.8–1.4) 1.1 (0.8–1.5)
Head and neck 0.07 (0.02) 0.05 (0.01) 0.38 1.4 (0.7–2.9) 0.8 (0.4–1.7) 1.1 (0.5–2.2)
Oral 0.07 (0.03) 0.03 (0.01) 0.21 2.0 (0.8–4.7) 1.1 (0.4–2.6) 1.0 (0.3–3.0)
Pharyngeal 0.06 (0.02) 0.03 (0.005) 0.18 2.2 (0.9–5.0) 1.3 (0.5–3.1) 1.3 (0.6–3.0)
Thyroid 0.48 (0.07) 0.31 (0.02) 0.019 1.5 (1.1–2.1) 1.1 (0.8–1.5) 1.1 (0.8–1.6)
Gastrointestinal 1.42 (0.12) 0.59 (0.03) ,0.0001 2.4 (2.0–2.9) 1.3 (1.1–1.5) 1.2 (0.9–1.5)
Colon 1.12 (0.10) 0.47 (0.02) ,0.0001 2.4 (2.0–2.9) 1.3 (1.0–1.6) 1.1 (0.9–1.4)
Esophageal Rare 0.02 (0.003) — ———
Liver 0.10 (0.04) 0.02 (0.01) 0.071 4.7 (1.7–12.7) 3.2 (1.1–9.3) 2.9 (0.9–9.6)
Pancreatic 0.08 (0.03) 0.02 (0.005) 0.032 3.6 (1.6–7.8) 2.0 (0.9–4.4) 2.5 (0.9–6.8)
Rectal 0.08 (0.03) 0.04 (0.01) 0.11 2.2 (1.1–4.7) 1.2 (0.6–2.4) 1.2 (0.5–2.8)
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Diabetes and cancer among U.S. adultsequality in the prevalence estimates was
tested with a two-sample t test. We con-
sidered results with a two-tailed P value
,0.05orthe95%CIofaprevalenceratio
estimate that did not include 1 to be sta-
tistically signiﬁcant.
We conducted all analyses using
SUDAAN 9.0 software (Research Triangle
Institute, Research Triangle Park, NC) to
accountforthecomplexsamplingdesign.
RESULTS—Theﬁnalanalyticsampleof
397,783individuals(meanage,46.8years;
range, 18–99 years or older; SE = 0.06
years) consisted of 151,459 men (38.1%),
318,070 non–Hispanic whites (80.0%),
31,168 non–Hispanic blacks (7.8%),
26,764 Hispanics (6.7%), and 21,781
other racial/ethnic participants (5.5%).
After adjustment for age and all other
potentialconfounders,menwithdiabetes
had signiﬁcantly higher prevalences of
cancer of all sites and cancers of the
prostate,colon,pancreas,rectum,urinary
bladder, and kidney than men without
diabetes (Table 1). Women with diabetes
had signiﬁcantly higher prevalences
of cancer of all sites and cancers of the
breast and endometrium as well as leuke-
mia than women without diabetes (all
P , 0.05). Diabetic men had a higher
prevalence of liver cancer, whereas dia-
betic women had a higher prevalence of
liver cancer and pancreatic cancer than
their nondiabetic counterparts, albeit no
statistical signiﬁcance was detected (P =
0.07–0.13).
CONCLUSIONS—Our prevalence ra-
tio estimates for the cancer of all sites
amongmenandwomenwerecomparable
to relative risk estimates in studies on
cancer incidence (3,9). Our results sup-
port an association between diabetes and
cancer.Previousﬁndingshaveshownthat
diabetes is linked to an increased risk of
cancers of the pancreas, liver, kidney, co-
lorectal, urinary bladder, endometrium,
breast, and non–Hodgkin’sl y m p h o m a
( 3 ) .T h ep o s s i b l eb i o l o g i cm e c h a n i s m s
that link diabetes and cancer include hy-
perinsulinemia, hyperglycemia, and/or
chronic inﬂammation (2).
Theseﬁndingshavesigniﬁcantpublic
health implications because the strong
associations of diabetes with certain can-
cer types may inform public health deci-
sions and policies regarding the priorities
of cancer screening and clinical manage-
ment. Regular screening is an important
tool to detect certain types of cancer early
intheironset,particularlythosewithhigh
prevalence among adults with diabetes.
As shown in a previous study (10), U.S.
women with diagnosed diabetes had low
ratesofscreeningforcancersofthebreast,
cervix, colon and rectum compared with
recommended levels. Moreover, diabetic
women were less likely to be screened for
cervical cancer compared with nondiabetic
women. Therefore, enhanced efforts may
be needed to promote cancer screening,
particularly for the cancers highly related
to diabetes, as evidenced in our study.
Our results were subject to several
limitations. First, although there is a sub-
stantial agreement in determinations of
diabetes status by self-reports and those
basedon actual diagnoses (11), misclassi-
ﬁcation bias of the diabetes status of par-
ticipants with undiagnosed diabetes
could have resulted in the underestima-
tion of our results. Second, the BRFSS
survey excludes adults who have been in-
stitutionalized or hospitalized and those
with only mobile telephones, which may
have led us to underestimate the true
prevalence of cancer.
Inconclusion,ourresultssuggestthat
adults with diabetes had a higher preva-
lence of cancer than those without di-
abetes. These ﬁndings highlight a need
for increased attention to and efforts in
Table 1—Continued
Cancer site/tract Cancer type
Crude prevalence, % (SE) Prevalence ratio (95% CI)
Diabetes No diabetes P Model 1* Model 2† Model 3‡
Stomach 0.04 (0.01) 0.03 (0.01) 0.40 1.4 (0.7–3.0) 0.8 (0.4–1.7) 0.9 (0.4–2.0)
Leukemia/lymphoma 0.63 (0.09) 0.36 (0.02) 0.0019 1.8 (1.3–2.4) 1.1 (0.9–1.5) 1.2 (0.8–1.6)
Hodgkin’s
lymphoma
0.17 (0.05) 0.12 (0.01) 0.34 1.4 (0.8–2.5) 1.0 (0.5–1.8) 1.0 (0.5–1.8)
Leukemia 0.30 (0.06) 0.10 (0.01) 0.0015 3.1 (1.9–4.9) 2.0 (1.3–3.4) 2.3 (1.3–4.2)
Non–Hodgkin’s
lymphoma
0.16 (0.03) 0.14 (0.01) 0.51 1.2 (0.8–1.8) 0.7 (0.5–1.1) 0.7 (0.4–1.1)
Skin 4.35 (0.20) 3.25 (0.06) ,0.0001 1.3 (1.2–1.5) 0.8 (0.7–0.9) 1.0 (0.9–1.2)
Melanoma 1.35 (0.12) 0.90 (0.03) 0.0004 1.5 (1.2–1.8) 0.9 (0.8–1.1) 1.2 (1.0–1.5)
Other skin 3.08 (0.16) 2.39 (0.05) 0.0001 1.3 (1.2–1.4) 0.7 (0.7–0.8) 1.0 (0.9–1.1)
Lung 0.37 (0.05) 0.24 (0.02) 0.0314 1.5 (1.1–2.2) 0.8 (0.6–1.2) 0.7 (0.4–1.1)
Urinary 0.43 (0.06) 0.19 (0.01) 0.0002 2.3 (1.7–3.2) 1.2 (0.9–1.7) 1.2 (0.8–1.6)
Bladder 0.19 (0.04) 0.10 (0.01) 0.009 2.0 (1.3–3.0) 1.0 (0.7–1.5) 0.9 (0.6–1.3)
Kidney 0.24 (0.05) 0.09 (0.01) 0.0071 2.6 (1.6–4.4) 1.6 (1.0–2.6) 1.6 (0.9–2.7)
Other sites 1.60 (0.15) 0.84 (0.04) ,0.0001 1.9 (1.6–2.3) 1.3 (1.0–1.5) 1.2 (0.9–1.4)
Heart Rare Rare — ———
Bone 0.05 (0.02) 0.05 (0.01) 0.94 1.0 (0.5–2.1) 0.9 (0.4–1.7) 0.9 (0.4–2.0)
Brain 0.04 (0.02) 0.06 (0.01) 0.54 0.7 (0.3–2.1) 0.8 (0.3–2.1) 0.7 (0.2–2.8)
Neuroblastoma Rare Rare — ———
Other 1.50 (0.14) 0.73 (0.03) ,0.0001 2.1 (1.7–2.5) 1.3 (1.1–1.6) 1.2 (1.0–1.5)
*Model1:unadjusted.†Model2:adjustedforage(years,continuous)only.‡Model3:adjustedforage(years,continuous),race/ethnicity(non–Hispanicwhite,non–
Hispanic black, Hispanic, other), health insurance coverage (any vs. none), smoking status (current smoker, former smoker, never smoked), heavy drinking (yes,
consumingmore than two drinksperdayamongmen andmore than one drink per day amongwomen vs.no),BMI (kg/m
2,continuous), and physical inactivity(yes
vs. no). §Rare: prevalence estimate is between 0 and 0.01%. Statistical tests are not provided due to insufﬁcient data.
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Li and Associatespreventing and screening for certain can-
cers to reduce the disease burden and
improve the quality of life among adults
with diabetes in the general population.
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